Description

Overview

Sermorelin is a synthetic version of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the minimal sequence needed for substantial GHRH receptor activity. By activating pituitary GHRH receptors, it can stimulate endogenous growth-hormone release while remaining subject to normal hypothalamic-pituitary feedback. Research has focused on GH stimulation testing, pediatric endocrinology, age-related endocrine physiology, and comparison with other GHRH analogs and secretagogues.

How It Works

• GHRH receptor activation: Sermorelin binds pituitary GHRH receptors and stimulates endogenous GH secretion.
• Physiologic feedback: Because signaling occurs upstream of GH release, normal somatostatin/GHRH feedback remains relevant.
• Downstream IGF-1 axis: Research can measure downstream changes in GH and IGF-1 signaling.

Research Areas

• Pituitary function
• Growth-hormone stimulation research
• Endocrine aging
• GHRH analog pharmacology

Research / Study Context

• Endocrine stimulation studies: Human studies use serial GH sampling and endocrine-response endpoints.
• Comparative secretagogue research: Studies compare GHRH analogs with other GH secretagogues or combinations.

Key Research Findings

• Sermorelin is a well-defined GHRH research tool.
• Evidence of GH release should not be converted into broad claims about anti-aging or body composition.
• Regulatory status should be described carefully and separately from historical use.

Related Research

• Ipamorelin
• Tesamorelin
• CJC-1295 No DAC + Ipamorelin

Scientific Reference Starter Set

• Peptide Education Hub: Sermorelin profile
• PubMed search: sermorelin GHRH 1-29 growth hormone
• PubMed search: GHRH 1-29 pituitary stimulation